Immungenetics AG: Last Patient Last Visit (LPLV) reached in first part of the DrainAD Study, a Phase 2 trial for the early diagnosis and causative treatment of Alzheimer's Disease (AD)
Immungenetics AG, a German based biopharmaceutical company focusing on novel treatments for unmet medical needs in the f…